⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 2, 2024

Table S3 from De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression

Naveen Kumar Tangudu Raquel Buj Hui Wang Jiefei Wang Aidan R. Cole Apoorva Uboveja Richard Fang Amandine Amalric Baixue Yang Adam Chatoff Claudia V. Crispim Peter Sajjakulnukit Maureen A. Lyons Kristine Cooper Nadine Hempel Costas A. Lyssiotis Uma Chandran Nathaniel W. Snyder Katherine M. Aird

View at Publisher

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

CRISPR screen results for human SKMEL28 cells

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tangudu et al. (2024) studied this question.

synapsesocial.com/papers/68e6bd48b6db64358763de7e https://doi.org/10.1158/2767-9764.25738365

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table S3 from <i>De Novo</i> Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression2024
2Table S4 from <i>De Novo</i> Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression2024
3Table S4 from <i>De Novo</i> Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression2024
4Table S5 from <i>De Novo</i> Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression2024
5Table S5 from <i>De Novo</i> Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression2024

More related papers

Table S1 from <i>De Novo</i> Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression2024
Table S1 from <i>De Novo</i> Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression2024
Table S2 from <i>De Novo</i> Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression2024